Letzte Aktualisierung: January 27, 2022
mRNA vaccine passes phase 1 clinical trials
One of China's mRNA vaccines against Covid is expected to achieve 95 percent efficacy in tests. This was shown by data from the first phase of clinical trials, reports business portal Caixin. The vaccine was jointly developed by Walvax Biotechnology and Suzhou Abogen Biosciences, as well as the Academy of Military Sciences of the Chinese People's Liberation Army, according to Caixin. It bears the designation Arcov.